METHOD DEVELOPMENT AND VALIDATION OF TIVOZANIB BY USING RP-HPLC IN BULK AND PHARMACEUTICAL DOSAGE FORM

T. JAISON JOSE; Y. SUBBAREDDY; K. SANKAR

doi:10.22159/ijap.2021v13i6.42701

Authors

T. JAISON JOSE Department of Chemistry, Andhra Loyola College, Vijayawada, AP 520008, India
Y. SUBBAREDDY Department of Chemistry, Andhra Loyola College, Vijayawada, AP 520008, India
K. SANKAR Department of Botany, Andhra Loyola College, Vijayawada, AP 520008, India

DOI:

https://doi.org/10.22159/ijap.2021v13i6.42701

Keywords:

Tivozanib, RP-HPLC, Development, Validation, ICH guidelines

Abstract

Objective: The current investigation was pointed at developing and progressively validating novel, simple, responsive and stable RP-HPLC method for the measurement of active pharmaceutical ingredient of Tivozanib.

Methods: A simple, selective, validated and well-defined stability that shows isocratic RP-HPLC methodology for the quantitative determination of Tivozanib. The chromatographic strategy utilized X-bridge phenyl column of dimensions 150x4.6 mm, 3.5 micron, using isocratic elution with a mobile phase of acetonitrile and 0.1 percent formic acid (50:50). A flow rate of 1 ml/min and a detector wavelength of 216 nm utilizing the PDA detector were given in the instrumental settings. Validation of the proposed method was carried out according to an international conference on harmonization (ICH) guidelines.

Results: LOD and LOQ for the two active ingredients were established with respect to test concentration. The calibration charts plotted were linear with a regression coefficient of R²>0.999, means the linearity was within the limit. Recovery, specificity, linearity, accuracy, robustness, ruggedness were determined as a part of method validation and the results were found to be within the acceptable range.

Conclusion: The proposed method to be fast, simple, feasible and affordable in assay condition. During stability tests, it can be used for routine analysis of the selected drugs.

Downloads

Download data is not yet available.

References

Van den Oever MC, Spijker S, Smit AB, De Vries TJ. Prefrontal cortex plasticity mechanisms in drug seeking and relapse. Neurosci Biobehav Rev. 2010;35(2):276-84. doi: 10.1016/j.neubiorev.2009.11.016, PMID 19932711.

Hudson A, Stamp JA. Ovarian hormones and propensity to drug relapse: a review. Neurosci Biobehav Rev. 2011;35(3):427-36. doi: 10.1016/j.neubiorev.2010.05.001, PMID 20488201.

Rini BI, Rathmell WK, Godley P. Renal cell carcinoma. Curr Opin Oncol. 2008;20(3):300-6. doi: 10.1097/ CCO.0b013e3282f9782b, PMID 18391630.

Quinn DI, Lara PN. Renal-cell cancer--targeting an immune checkpoint or multiple kinases. N Engl J Med. 2015;373(19):1872-4. doi: 10.1056/NEJMe1511252, PMID 26406149.

Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615-21. doi: 10.1016/j.eururo.2011.06.049, PMID 21741761.

Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem. 2006;75:93-109. doi: 10.1146/annurev.biochem.75.103004.142657, PMID 16756486.

Mills RJ, Young CA, Pallant JF, Tennant A. Development of a patient reported outcome scale for fatigue in multiple sclerosis: the neurological fatigue index (NFI-MS). Health Qual Life Outcomes. 2010;8:22. doi: 10.1186/1477-7525-8-22, PMID 20152031.

Lackland DT, Weber MA. Global burden of cardiovascular disease and stroke: hypertension at the core. Can J Cardiol. 2015;31(5):569-71. doi: 10.1016/j.cjca.2015.01.009, PMID 25795106.

Musini VM, Gueyffier F, Puil L, Salzwedel DM, Wright JM. Pharmacotherapy for hypertension in adults aged 18 to 59 y. Cochrane Database Syst Rev. 2017;2017(8):CD008276. doi: 10.1002/14651858.CD008276.pub2.

Kaplan RJ, Greenwood CE. Influence of dietary carbohydrates and glycaemic response on subjective appetite and food intake in healthy elderly persons. Int J Food Sci Nutr. 2002;53(4):305-16. doi: 10.1080/09637480220138160, PMID 12090026.

Van Houtte E, Van Lierde K, Claeys S. Pathophysiology and treatment of muscle tension dysphonia: a review of the current knowledge. J Voice. 2011;25(2):202-7. doi: 10.1016/j.jvoice.2009.10.009.

Pantalone KM, Hatipoglu BA. Hyponatremia and the thyroid: causality or association? J Clin Med. 2014;4(1):32-6. doi: 10.3390/jcm4010032, PMID 26237016.

Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA Guidelines: The use of L-T4+L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1(2):55-71. doi: 10.1159/000339444, PMID 24782999.

Goldsobel AB, Chipps BE. Cough in the pediatric population. J Pediatr. 2010;156(3):352-8. doi: 10.1016/j.jpeds.2009.12.004, PMID 20176183.

Fourie J, van Heerden WF, McEachen SC, van Zyl A. Chronic ulcerative stomatitis: a distinct clinical entity? SADJ. 2011;66(3):119-21. PMID 21874892.

Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician. 1999;59(8):2223-30. PMID 10221307.

Gowda S, Desai PB, Hull VV, Math AA, Vernekar SN, Kulkarni SS. A review on laboratory liver function tests. Pan Afr Med J. 2009;3:17. PMID 21532726.

Cerrizuela S, Vega Lopez GA, Aybar MJ. The role of teratogens in neural crest development. Birth Defects Res. 2020;112(8):584-632. doi: 10.1002/bdr2.1644, PMID 31926062.

Bellinger DC. Teratogen update: lead and pregnancy. Birth Defects Res A Clin Mol Teratol. 2005;73(6):409-20. doi: 10.1002/bdra.20127, PMID 15880700.

Qiu H, Mathäs M, Nestler S, Bengel C, Nem D, Gödtel Armbrust U, Lang T, Taudien S, Burk O, Wojnowski L. The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenet Genomics. 2010;20(3):167-78. doi: 10.1097/FPC.0b013e328336bbeb, PMID 20147837.

Bishop Bailey D, Thomson S, Askari A, Faulkner A, Wheeler Jones C. Lipid-metabolizing CYPs in the regulation and dysregulation of metabolism. Annu Rev Nutr. 2014;34:261-79. doi: 10.1146/annurev-nutr-071813-105747, PMID 24819323.

Birbrair A, Zhang T, Wang ZM, Messi ML, Olson JD, Mintz A, Delbono O. Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol. 2014;307(1):C25-38. doi: 10.1152/ajpcell.00084.2014, PMID 24788248.

McDougall SR, Anderson AR, Chaplain MA. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol. 2006;241(3):564-89. doi: 10.1016/j.jtbi.2005.12.022, PMID 16487543.

Campas C, Bolos J, Castaner R. Tivozanib. Drugs Fut. 2009;34(10):793-6. doi: 10.1358/dof.2009.034.10.1417872.

Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 2000;19(49):5598-605. doi: 10.1038/sj.onc.1203855, PMID 11114740.

Stuttfeld E, Ballmer Hofer K. Structure and function of VEGF receptors. IUBMB Life. 2009;61(9):915-22. doi: 10.1002/iub.234, PMID 19658168.

Zygmunt T, Gay CM, Blondelle J, Singh MK, Flaherty KM, Means PC, Herwig L, Krudewig A, Belting HG, Affolter M, Epstein JA, Torres Vazquez J. Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. Dev Cell. 2011;21(2):301-14. doi: 10.1016/j.devcel.2011.06.033, PMID 21802375.

Badal S, Delgoda R. Role of the modulation of CYP1A1 expression and activity in chemoprevention. J Appl Toxicol. 2014;34(7):743-53. doi: 10.1002/jat.2968, PMID 24532440.

Yang G, Ge S, Singh R, Basu S, Shatzer K, Zen M, Liu J, Tu Y, Zhang C, Wei J, Shi J, Zhu L, Liu Z, Wang Y, Gao S, Hu M. Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metab Rev. 2017;49(2):105-38. doi: 10.1080/03602532.2017.1293682, PMID 28266877.

Cijo M. Xavier, Kanakapura Basavaiah. RP-UPLC Development and validation of metformin hydrochloride in pure drug and pharmaceutical formulations. World J Pharm Pharm Sci. 2015;4:1649-68.

Sri Girija K, Bikshal Babu K, Venkateswara Rao A. A new high -performance liquid chromatography method for the separation and simultaneous quantification of Eeptifibatide and its impurities in pharmaceutical injection formulation. Int J Appl Pharm. 2021;13:165-72.

VLN Balaji Gupta, VLN T Venkateswara Rao B, Kishore Bbabu B. RP-HPLC (stability indicating) based assay method for the simultaneous estimation of Doravirine, tenofovir disoproxil fumarate and lamivudine. Int J Appl Pharm. 2021;13:153-9.

Murali Krishnam Raju P, Venkata Narayana B, Shyamala P, Srinivasu K, HSN Raju HSN D. A validated RP-HPLC method for impurity profiling of Sodium nitroprusside in injection dosage form. Int J Appl Pharm. 2021;13:160-9.

Sanathoiba Singha L, Srinivasa Rao T. Development and validation of an RP-HPLC method for the determination of Uulipristal acetate in pharmaceutical dosage form. Asian J Pharm Clin Res. 2021;14:83-9.

Asha Eluru A, Surendra Babu K. A study of method development, validation and forced degradation for simultaneous quantification of povidone iodine and ornidazole in bulk and pharmaceutical dosage form by using RP-HPLC. Int J Res Pharm Sci. 2021;12:1217-22.

Malathi S, Devakumar D. Development and validation of rp-hplc method for the estimation of escitalopram oxalate and flupentixol dihydrochloride in combined dosage form and plasma. Int J Pharm Pharm Sci. 2021;13:61-6.

Syed Rafi, Kantipudi Rambabu. Stability indicating validated HPLC method for the determination of aceclofenac and misoprostol in bulk and pharmaceutical formulation. IJRPS 2020;11(4):7848-53. doi: 10.26452/ijrps.v11i4.4669.

Gunturu Raviteja, Kantipudi Rambabu. A study of development and validation of a method for simultaneous estimation of cidofovir and famciclovir using RP-HPLC. IJRPS 2020;11(4): 7878-84. doi: 10.26452/ijrps.v11i4.4673.

Vijayakumari M, Balasekhar Reddy Ch B. Stability indicating validated hplc method for the determination of zanubrutinib in bulk and pharmaceutical dosage form. Asian J Pharm Clin Res. 2020;13:159-62.

Charu Pandya P, Sadhana Rajput J. Development and validation of stability indicating method RP-HPLC method of Aacotiamide. Int J Pharm Pharm Sci. 2018;10:1-8.

Athavia BA, Dedania ZR, Dedania RR, Swamy SMV, Prajapati CB. Stability indicating HPLC method for determination of vilazodone hydrochloride. Int J Curr Pharm Sci 2017;9(4):123-9. doi: 10.22159/ijcpr.2017v9i4.20975.

METHOD DEVELOPMENT AND VALIDATION OF TIVOZANIB BY USING RP-HPLC IN BULK AND PHARMACEUTICAL DOSAGE FORM

Authors

DOI:

Keywords:

Abstract

Downloads

References

Published

How to Cite

Issue

Section